DCPH - Deciphera Pharmaceuticals Inc Stock Price, Fair Value and News

$25.59

Market Closed as of 11 Jun 2024, 04:00 pm ET

DCPH Stock Valuation Analysis

Valuation

Max Portfolio %

DCPH Price Action

DCPH RSI Chart

DCPH Stock Valuation Analysis

Valuation

Max Portfolio %

DCPH Valuation

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

DCPH Fundamentals

DCPH Revenue

DCPH Earnings

DCPH Profitability

DCPH Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

Net sales

Year	Q1	Q2	Q3	Q4
2024	174.9M	-	-	-
2023	138.3M	144.1M	151.4M	163.4M
2022	100.2M	109.1M	121.9M	134.0M
2021	67.2M	83.7M	91.4M	96.1M
2020	-	30.7M	36.4M	42.1M
2019	-	-	-	25.0M

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Deciphera Pharmaceuticals Inc

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Steven L. Hoerter
WEBSITE	deciphera.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	300